C12N 2760/14034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/14034 (Use of virus or viral component as vaccine) appears on 12 US grants and 22 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 22
- Assignees
- 25
- Inventors
- 59
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 0 | 0 |
| 2016 | 2 | 3 |
| 2017 | 1 | 0 |
| 2018 | 0 | 2 |
| 2019 | 1 | 1 |
| 2020 | 1 | 2 |
| 2021 | 1 | 3 |
| 2022 | 1 | 4 |
| 2023 | 2 | 0 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric filovirus vaccines10 Feb 2026US 12,545,709 B2Katholieke Universiteit Leuven
- Chimeric molecules and uses thereof15 Oct 2024US 12,116,386 B2The University of Queensland
- Peptide fragments from filoviruses and their uses5 Dec 2023US 11,833,199 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Stabilized Filovirus glycoprotein trimers14 Mar 2023US 11,603,390 B2Janssen Vaccines & Prevention B. V.
- Chimeric molecules and uses thereof22 Feb 2022US 11,254,712 B2The University of Queensland
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Novel vsv virus formulations7 May 2026US 2026/0124288 A1Emergent Product Development Gaithersburg Inc.
- Antibodies targeting marburgvirus glycoproteins and uses thereof27 Mar 2025US 2025/0099570 A1Government of the United States of America, AS Represented By the Secretary of Commerce
- Chimeric filovirus vaccines22 Dec 2022US 2022/0402976 A1Katholieke Universiteit Leuven
- Chimeric molecules and uses thereof28 Apr 2022US 2022/0127309 A1The University of Queensland
Most cited
By later US patents
- Invasive bacterial vectors for expressing alphavirus replicons13US 6,531,313 B1International AIDS Vaccine Initiative · 2003
- Compositions and methods for the treatment of viral infections5US 9,290,545 B2Dana-Farber Cancer Institute, Inc. · 2016
- Compositions and methods comprising hydrocarbon-stapled polypeptides4US 10,259,848 B2Dana-Farber Cancer Institute, Inc. · 2019
- Methods and assays for treating filoviridae infections3US 9,234,885 B2Albert Einstein College of Medicine · 2016
- Chimeric molecules and uses thereof2US 11,254,712 B2The University of Queensland · 2022